Having trouble accessing articles? Reset your cache.

June 10 Clinical Quick Takes: Oral semaglutide superior to Jardiance, non-inferior to Victoza; plus Aptinyx and Eli Lilly

Novo’s oral semaglutide meets in Phase III trials
Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported results from two Phase III trials of its oral semaglutide in Type II diabetes.

Read the full 288 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE